Recent advances in understanding and treating vasculitis

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are near universally fatal conditions if untreated. Although effective therapeutic options are available for these diseases, treatment regimens are associated with both short- and long-term adverse effects. The recent identification of effective B-cell-targeted therapy with an anti-CD20 monoclonal antibody has transformed the treatment landscape of AAV. Questions, nevertheless, remain regarding the appropriate timing, dose, frequency, duration, and long-term effects of treatment. The aim of this article is to provide an overview of the current information, recent advances, ongoing clinical trials, and future treatment possibilities in AAV.

Medienart:

E-Artikel

Erscheinungsjahr:

2016

Erschienen:

2016

Enthalten in:

Zur Gesamtaufnahme - volume:5

Enthalten in:

F1000Research - 5(2016) vom: 01.

Sprache:

Englisch

Beteiligte Personen:

Koster, Matthew J [VerfasserIn]
Warrington, Kenneth J [VerfasserIn]

Links:

Volltext

Themen:

ANCA-associated vasculitides
B-cell
Journal Article
Review
Systemic vasculitides
Vasculitis

Anmerkungen:

Date Completed 27.06.2016

Date Revised 13.11.2018

published: Electronic-eCollection

Citation Status PubMed-not-MEDLINE

doi:

10.12688/f1000research.8403.1

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM261791109